LONDON, UNITED KINGSDOM--(MARKET WIRE)--Aug 5, 2008 -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Schering-Plough Corporation: PharmaVitae Profile

http://www.reportlinker.com/p091757/Schering-Plough-Corporation-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

- Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector

- Analyze the impact of Schering-Plough's acquisition of Organon Biosciences, completed in 2007

- Assess the diversity of Schering-Plough's product portfolio in light of forecast declining sales for its recent sales growth driver Zetia/Vytorin

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Schering-Plough: PharmaVitae forecasts at a glance 7

Strategic insight 8

Five principal events orchestrate SGP's performance as action agenda progresses 8

Business-model crumbles under pressure from loratadine generics 8

Widening portfolio to helps restore sales growth 9

SGP 'Build the Base' phase in a single move through the OBS acquisition 12

ENHANCE trial fallout threatens Zetia/Vytorin income stream 13

Cost-cutting implementations and pipeline to drive long-term profit growth 15

SWOT analysis 16

Strengths 16

Weaknesses 19

Opportunities 20

Threats 22

CHAPTER 3 QUARTERLY NEWS UPDATE 26

Key findings 26

Product developments 27

Deals and alliances 28

Product deals 28

Technology deals 28

M&A activity 29

Company announcements 29

Future product milestones 30

CHAPTER 4 COMPANY STRUCTURE 31

Key findings 31

Company overview 32

Company history 33

M&A history 35

Schering Corp merger with Plough Corp 35

Neogenesis 35

Organon Biosciences 35

M&A strategy 36

CHAPTER 5 COMPANY SALES 38

Key findings 38

Prescription pharmaceutical sales and growth rate analysis, 2001-13 39

Historical analysis 40

Forecast analysis 40

Product analysis 42

Product analysis, 2001-07 42

Product analysis, 2007-13 44

Therapy area analysis 49

Therapy area analysis, 2001-07 50

Therapy area analysis, 2007-13 52

Therapy area focus, 2001-13 57

Geographic analysis 59

Geographic analysis, 2001-07 60

Geographic analysis, 2007-13 62

Geographic focus, 2001-13 64

Launch/core/expiry analysis 66

Explanation of launch/core/expiry analysis 66

Launch analysis, 2007-13 67

Core analysis, 2007-13 68

Expiry analysis, 2007-13 69

Launch/core/expiry configuration, 2007-13 71

Molecule type analysis 72

Molecule type analysis, 2001-07 73

Molecule type analysis, 2007-13 74

Externalization analysis 78

Externalization analysis, 2001-07 79

Externalization analysis, 2007-13 81

CHAPTER 6 COMPANY FINANCIALS 85

Key findings 85

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 86

Financial statements, 2001-07 88

Profit and loss account, 2001-07 88

Balance sheet, 2001-07 90

Operating costs and profit analysis 92

Operating costs and profit analysis, 2001-07 93

Operating cost ratio and profit margin analysis, 2001-07 95

Operating cost ratio and profit margin analysis, 2007-13 96

Operating costs and profit analysis, 2007-13 99

Return on capital employed analysis 102

Capital employed analysis, 2001-07 103

Return on capital employed (RoCE) analysis, 2001-07 106

Market capitalization analysis 109

Market capitalization analysis 2001-07 109

Total shareholder returns analysis 2001-07 110

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 112

Key findings 112

Overview 114

Urology & gender-specific health 115

NuvaRing 115

Sales forecasts 117

Respiratory 120

Nasonex 120

Sales forecast 122

Infectious diseases 124

Intron franchise 124

Sales forecasts 127

Immunology & inflammation 130

Remicade/golimumab 130

Sales forecasts 132

Central nervous system 135

Asenapine 135

Sales forecasts 137

Bridion 141

Sales forecasts 142

Cardiovascular 144

Zetia/Vytorin 144

Sales forecast 145

Oncology 149

Temodar 149

Sales forecasts 151

CHAPTER 8 APPENDIX 153

R&D pipeline 153

References 155

Abbreviations 156

List of Tables

Table 1: Schering-Plough - PharmaVitae forecasts at a glance 7

Table 2: OBS acquisition builds the base 13

Table 3: Key product developments, Q1 2008 27

Table 4: Schering-Plough product deals and alliances, Q1 2008 28

Table 5: Schering-Plough technology deals and alliances, Q1 2008 28

Table 6: Schering-Plough M&A activity, Q1 2008 29

Table 7: Schering-Plough company announcements, 2008 29

Table 8: Schering-Plough future product milestones 2008-09 30

Table 9: Schering-Plough product portfolio overview, global sales ($m), 2001-07 42

Table 10: Schering-Plough product portfolio overview, global sales ($m), 2007-13 44

Table 11: Schering-Plough therapy portfolio overview, sales ($m), 2001-07 50

Table 12: Schering-Plough therapy portfolio overview, sales ($m), 2007-13 52

Table 13: Schering-Plough portfolio overview by geographic region, sales ($m), 2001-07 60

Table 14: Schering-Plough portfolio overview by geographic region, sales ($m), 2007-13 62

Table 15: Schering-Plough launch portfolio overview ($m), 2007-13 67

Table 16: Schering-Plough core portfolio overview ($m), 2007-13 68

Table 17: Schering-Plough expiry portfolio overview ($m), 2007-13 69

Table 18: Schering-Plough portfolio overview by molecule type ($m), 2001-07 73

Table 19: Schering-Plough product portfolio overview by molecule type ($m), 2007-13 74

Table 20: Schering-Plough product portfolio overview by source ($m), 2001-07 79

Table 21: Schering-Plough product portfolio overview by source ($m), 2007-13 81

Table 22: Total Schering-Plough sales by business unit ($m), 2001-07 86

Table 23: Schering-Plough profit and loss account ($m), 2001-07 88

Table 24: Schering-Plough balance sheet ($m), 2001-07 90

Table 25: Schering-Plough operating revenue/cost analysis ($m), 2001-07 93

Table 26: Schering-Plough operating cost ratio analysis (% of total revenues), 2001-07 95

Table 27: Schering-Plough operating cost ratio analysis (% of total revenues), 2007-13 96

Table 28: Schering-Plough operating revenue/cost analysis ($m), 2007-13 99

Table 29: Schering-Plough capital employed ($m), 2001-07 103

Table 30: Schering-Plough EBIT return on capital employed ($m), 2001-07 106

Table 31: Schering-Plough EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07 107

Table 32: SGP market capitalization vs. S&P 500 ($ billion), 2001-07 109

Table 33: Schering-Plough total shareholder returns (annual %), 2001-07 110

Table 34: Key products overview, sales ($m) 114

Table 35: NuvaRing: overview 115

Table 36: NuvaRing: sales forecast ($m), 2007-13 117

Table 37: Oral contraceptive market, sales ($m), 2001-13 118

Table 38: Nasonex: overview 121

Table 39: Nasonex: sales forecast ($m), 2007-13 122

Table 40: Top four nasal corticosteroids, sales ($m), 2001-07 123

Table 41: Peg-Intron: overview 124

Table 42: Intron A: overview 125

Table 43: Rebetol: overview 126

Table 44: Peg-Intron & Intron A: sales forecast ($m), 2007-13 127

Table 45: Rebetol: sales forecast ($m), 2007-13 127

Table 46: Remicade: overview 130

Table 47: Golimumab: overview 131

Table 48: Remicade: sales forecast ($m), 2007-13 132

Table 49: Golimumab: sales forecast ($m), 2006-12 132

Table 50: Anti-TNF market overview 133

Table 51: Asenapine: overview 135

Table 52: Asenapine: sales forecast ($m), 2007-13 137

Table 53: Bridion: overview 141

Table 54: Bridion: sales forecast ($m), 2007-13 142

Table 55: Phase III efficacy results of Bridion vs Neostigmine 143

Table 56: Zetia/Vytorin: overview 144

Table 57: Zetia/Vytorin: sales forecast ($m), 2007-13 145

Table 58: Major dyslipidemia therapeutics, sales ($m), 2001-07 146

Table 59: Temodar: overview 149

Table 60: Temodar: sales forecast ($m), 2007-13 151

Table 61: Schering-Plough's R&D pipeline (Phase I-registration) 153

Table 62: Schering-Plough's indication broadening pipeline (Phase I-registration) 155

List of Figures

Figure 1: Schering-Plough prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5

Figure 2: Schering-Plough financial performance ($m), 2001-13 6

Figure 3: Five events dominate SGP's five-phase action agenda timeline 8

Figure 4: Claritin triggered profit decay ($m), 2001-04 9

Figure 5: SGP's portfolio expansion, sales ($m), 2001-07 10

Figure 6: Schering-Plough SWOT analysis 16

Figure 7: Schering-Plough prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 39

Figure 8: Schering-Plough key sales growth driver & resistors ($m), 2001-07 43

Figure 9: Schering-Plough key sales growth drivers & resistors ($m), 2007-13 46

Figure 10: Schering-Plough prescription pharmaceutical sales by therapy area ($m), 2001-13 49

Figure 11: Schering-Plough prescription pharma sales by therapy area, (% of total), 2001-13 57

Figure 12: Schering-Plough prescription pharmaceutical sales by geographic region ($m), 2001-13 59

Figure 13: Schering-Plough drivers and resistors by geographic region, sales ($m), 2001-07 60

Figure 14: Schering-Plough drivers and resistors by geographic region, sales ($m), 2007-13 62

Figure 15: Schering-Plough prescription pharmaceutical sales by geographic region (% of total), 2001-13 64

Figure 16: Schering-Plough launch/core/expiry configuration ($m), 2007-13 71

Figure 17: Schering-Plough prescription pharmaceutical sales by molecule type ($m), 2001-13 72

Figure 18: Schering-Plough growth drivers & resistors by molecule type ($m), 2007-13 76

Figure 19: Schering-Plough prescription pharmaceutical sales by source ($m), 2001-13 78

Figure 20: Schering-Plough growth drivers & resistors by source ($m), 2001-07 79

Figure 21: Schering-Plough growth drivers & resistors by source ($m), 2007-13 83

Figure 22: Schering-Plough operating revenue/cost analysis ($m), 2001-13 92

Figure 23: Schering-Plough operating cost ratio analysis (% of total revenues), 2001-13 98

Figure 24: Schering-Plough return on capital employed, EBIT margin and capital turnover, 2001-07 102

Figure 25: Return on capital employed formula 108

Figure 26: SGP market cap vs. S&P 500 ($ billion), 2001-07 110

Figure 27: SGP total shareholder returns vs. S&P 500, 2001-07 ($m) 111

Figure 28: Schering-Plough's Hep C franchise, sales ($m), 2001-13 129

Figure 29: Dyslipidemia treatment sales ($m), 2001-07 147

To order this report:

Schering-Plough Corporation: PharmaVitae Profile

http://www.reportlinker.com/p091757/Schering-Plough-Corporation-PharmaVitae-Profile.html

More market research reports here!

     Contacts:
     Reportlinker.com
     Nicolas
     (718) 887-3024
     Email: nbo@reportlinker.com